Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Jan 13, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 13, 2025
Period End
January 12, 2025
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. filed this Current Report on Form 8-K under Item 2.02 to furnish a January 12, 2025 press release announcing preliminary, unaudited financial results for the fiscal year ended January 3, 2025, along with fiscal year 2025 financial guidance and an update on its business.

The company stated that the audit of its fiscal 2024 financial statements is ongoing and could change the information in the press release, and that it will report audited results on February 11, 2025. Preliminary fiscal 2024 figures show total revenues of approximately $2.165 billiona and net product revenues of approximately $1.805 billion, which the company describes as cabozantinib franchise U.S. net product revenues. Research and development expenses were approximately $910 million and selling, general and administrative expenses approximately $495 million, with ending cash and marketable securities of approximately $1.75 billion.

Fiscal 2025 guidance calls for total revenues of $2.15 billion to $2.25 billionb and net product revenues of $1.95 billion to $2.05 billion, with R&D expenses of $925 million to $975 million, SG&A of $475 million to $525 million, and an effective tax rate of 21% to 23%. The guidance does not reflect any revenue from a potential U.S. launch of CABOMETYX in previously treated advanced neuroendocrine tumors, for which the FDA has a PDUFA target action date of April 3, 2025. The press release also updates pipeline priorities, including expansion of the zanzalintinib pivotal program, early-stage data readouts expected in 2025, and planned IND filings for three biotherapeutic programs.

The company has repurchased $205.6 millionc of stock under a program authorized for up to $500 million through the end of 2025. The information is furnished, not filed, under Item 2.02.

Key Highlights

  1. Preliminary fiscal 2024 total revenues of approximately $2.165 billion and net product revenues of approximately $1.805 billion
  2. Fiscal 2025 guidance: total revenues of $2.15 billion to $2.25 billion and net product revenues of $1.95 billion to $2.05 billion
  3. Guidance excludes any revenue from a potential U.S. launch of CABOMETYX in previously treated advanced NET; FDA PDUFA target action date is April 3, 2025
  4. Preliminary results are unaudited; the audit is ongoing and may change the figures, with audited results due February 11, 2025
  5. Zanzalintinib pivotal program expanding to six ongoing or planned trials, with several data readouts expected in the second half of 2025
  6. Stock repurchase program: $205.6 million repurchased at an average price of $33.62 per share under a program of up to $500 million through the end of 2025
  7. Preliminary fiscal 2024 ending cash and marketable securities of approximately $1.75 billion; fiscal 2025 cash guidance not provided

Frequently Asked Questions

  1. What are the key preliminary financial results for fiscal year 2024?

    The company reported preliminary total revenues of approximately $2.165 billion and net product revenues of approximately $1.805 billion. Research and development expenses were approximately $910 million, SG&A approximately $495 million, and ending cash and marketable securities approximately $1.75 billion. These figures are unaudited and subject to change.

  2. What is the fiscal 2025 financial guidance?

    Guidance calls for total revenues of $2.15 billion to $2.25 billion and net product revenues of $1.95 billion to $2.05 billion. R&D expenses are expected at $925 million to $975 million, SG&A at $475 million to $525 million, and the effective tax rate at 21% to 23%. The company states that cost of goods sold will be 4% to 5% of net product revenues.

  3. Does the guidance include a potential neuroendocrine tumor launch?

    No. The company states that net product and total revenues guidance do not reflect any revenue from a potential U.S. regulatory approval and commercial launch of CABOMETYX for previously treated advanced neuroendocrine tumors. The FDA is reviewing the supplemental NDA, with a PDUFA target action date of April 3, 2025.

  4. When will audited results be available and could they differ?

    The company will report audited fiscal 2024 results on February 11, 2025. The filing states that the audit is ongoing and could result in changes to the information in the press release, and that the preliminary figures may differ, perhaps materially, from the audited results.

  5. What are the key pipeline and capital allocation priorities for 2025?

    Priorities include the zanzalintinib pivotal program, with early-stage readouts from STELLAR-001 and STELLAR-002 expected in the first half of 2025, and planned IND filings for three biotherapeutic programs. The company also plans to use its balance sheet for GU and GI oncology business development and free cash flow for its stock repurchase program, under which it has repurchased $205.6 million of stock to date.